Evidence map›Paper›PMID 37284201›Full record

ArticleFrontiers in oncology2023

[

Zhenfeng Liu, Guanghua Wen, Yuqiao Huang, Yanzhao Dong, Zewei Wang, Ahmad Alhaskawi, Shuyi Zhang, GuoLin Wang, Qianni Ye, Haiying Zhou and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Zhenfeng LiuDepartment of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Guanghua WenDepartment of Nuclear Medicine, Shenzhen Longhua District Central Hospital, Shenzhen, China.
Yuqiao HuangInstitute of Translational Medicine, Zhejiang University, Hangzhou, China.
Yanzhao DongInstitute of Translational Medicine, Zhejiang University, Hangzhou, China.
Zewei WangDepartment of Clinical Medicine, Zhejiang University School of Medicine, Hangzhou, China.
Ahmad AlhaskawiDepartment of Orthopedics, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Shuyi ZhangDepartment of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
GuoLin WangDepartment of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Qianni YeDepartment of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Haiying ZhouDepartment of Orthopedics, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Hui LuDepartment of Orthopedics, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Mengjie DongDepartment of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
First Affiliated Hospital Zhejiang University · CNZhejiang University · CNLonggang Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The cell adhesion molecule (CAM) N-cadherin has become an important target for tumor therapy. The N-cadherin antagonist, ADH-1, exerts significant antitumor activity against N-cadherin-expressing cancers. Methods: In this study, [ Results: Radiolabeling of ADH-1 with [ Conclusion: [

Indexed as

[18 F]AlF-NOTA-ADH-1cancerEMTN-cadherinPET imaging probe

Identifiers

PMID37284201
PMCPMC10239968
OpenAlexW4377286946

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.